Update about Oralair® as a treatment for grass pollen allergic rhinitis - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Article Dans Une Revue Human Vaccines & Immunotherapeutics Année : 2022

Update about Oralair® as a treatment for grass pollen allergic rhinitis

Ralph Mösges
de Yun Wang
Robyn E. O’hehir
Catherine Bos
Efstrathios Karagiannis

Résumé

Sublingual immunotherapy (SLIT) is a well-tolerated, safe, and effective approach to treating allergic rhinitis (AR). Oralair® is a five-grass pollen SLIT tablet containing natural pollen allergens from five of the major grass species responsible for seasonal AR due to grass pollen allergy. Recommended use is in a pre-coseasonal regimen, starting daily treatment approximately 4 months before the start of the pollen season, with treatment then continued daily throughout the season; treatment should continue for 3-5 y. Clinical efficacy and safety of Oralair® in patients with grass pollen-induced AR has been demonstrated in a comprehensive clinical development program of randomized controlled trials. Effectiveness has been substantiated in subsequent observational studies with sustained efficacy following treatment cessation and a favorable level of adherence, quality of life, benefit, and satisfaction for the patients. Supportive evidence for a benefit in reducing the risk or delaying the development of allergic asthma is emerging.
Fichier principal
Vignette du fichier
Update about Oralair as a treatment for grass pollen allergic rhinitis.pdf (971.77 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification

Dates et versions

hal-03935968 , version 1 (12-01-2023)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Ludger Klimek, Randolf Brehler, Ralph Mösges, P. Demoly, Joaquim Mullol, et al.. Update about Oralair® as a treatment for grass pollen allergic rhinitis. Human Vaccines & Immunotherapeutics, 2022, 18 (5), pp.e2066424. ⟨10.1080/21645515.2022.2066424⟩. ⟨hal-03935968⟩
34 Consultations
73 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More